Rapport Therapeutics (RAPP) Income from Continuing Operations (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Income from Continuing Operations of 143692000.0 for Q1 2026, up 98.82% year-over-year from 72271280.44 in Q1 2025, and up 2.65% quarter-over-quarter from 147602000.0 in Q4 2025.
Powered by 
Analysis
Rapport Therapeutics (RAPP) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Income from Continuing Operations for 4 consecutive years, with 143692000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 98.82% year-over-year to 143692000.0; the TTM figure through Mar 2026 stood at 474112000.0 (up 96.13% YoY), while the FY2025 annual figure was 225322000.0, down 187.74% from the prior year.
- Income from Continuing Operations advanced to 143692000.0 in Q1 2026 per RAPP's latest filing, from 147602000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6411000.0 in Q2 2023 and bottomed at 12209361000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 1065252416.67 across 4 years, with a median of 19050500.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations sank 79809.42% — and 2026, when it surged 98.82%.
- Rapport Therapeutics' Income from Continuing Operations stood at 13519000.0 in 2023, then sank by 47.79% to 19980000.0 in 2024, then plunged by 638.75% to 147602000.0 in 2025, then rose by 2.65% to 143692000.0 in 2026.
- Business Quant data shows RAPP's Income from Continuing Operations at 143692000.0 in Q1 2026, 147602000.0 in Q4 2025, and 139286000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rapport Therapeutics | 2.22 Bn | 2.22 Bn | - | -56.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -56.62 Mn |
| Mar 31, 2026 | -19.86 Mn |
| Dec 31, 2025 | -33.76 Mn |
| Sep 30, 2025 | -26.93 Mn |
| Jun 30, 2025 | -26.73 Mn |
| Mar 31, 2025 | -24.06 Mn |
| Dec 31, 2024 | -19.98 Mn |
| Sep 30, 2024 | -17.54 Mn |
| Jun 30, 2024 | -18.12 Mn |
| Mar 31, 2024 | -15.28 Mn |
| Dec 31, 2023 | -13.52 Mn |
| Sep 30, 2023 | -8.71 Mn |
| Jun 30, 2023 | -6.41 Mn |